Milgosense

Incorporated December 2023 MilgoSense, an early-stage venture that seeks to disrupt the future of schizophrenia diagnosis, monitoring, and decision-making using simple, non-invasive, cheap, remote and AI-based diagnostic tool. Schizophrenia is a severe, chronic, and disabling mental disorder affecting approximately 1.1% of the population worldwide. It represents a significant economic burden for patients, payers, and society. Current annual US healthcare estimated costs exceed $155B. It usually starts in teenagers, where the symptoms are confusing and not easy to differentiate from somewhat more typical states of mind at this age. Early diagnosis and treatment may help get symptoms under control and may reduce the need for costly long-term hospitalizations. Early treatment entry may reduce hospitalizations and increase independent living by 41.5–46% and employment by 42–58%. The fundamental unmet need we wish to address is the lack of an objective decision-support tool to help prioritize and bring those teenagers in distress as soon as possible to a trained psychiatrist before it is too late. For more information, please contact Dr. Dovi Kelman @ dovi@milgosense.com